Publication | Closed Access
Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn’s disease and ulcerative colitis – experiences from a single center
24
Citations
24
References
2017
Year
This study confirmed the long-term efficacy and safety of CT-P13 therapy in IBD. Response rates at week 54 were similar in CD and UC.
| Year | Citations | |
|---|---|---|
Page 1
Page 1